Hua J, Zhang W, Cao H, et al. Effect of PIFR-based optimised inhalation therapy in patients recovering from acute exacerbation of chronic obstructive pulmonary disease: protocol of a prospective, multicentre, superiority, randomised controlled trial. BMJ Open 2020;10:e034804. doi: 10.1136/bmjopen-2019-034804.
The authors want to alert readers to the following update in the published version.
On page 3 the line “Spiriva HandiHaler (18 µg once a day) or Spiriva Respimat (2.5 µg once a day, Boehringer Ingelheim Pharma & Co KG) will be given in combination with ICS/LABA” has been corrected to “Spiriva HandiHaler (18 µg once a day) or Spiriva Respimat (2.5 µg twice a day, Boehringer Ingelheim Pharma & Co KG) will be given in combination with ICS/LABA.”